A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincistrine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects > or = 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Phase of Trial: Phase III
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Vincristine (Primary) ; Antineoplastics
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms HALLMARQ
- Sponsors Spectrum Pharmaceuticals
- 08 Dec 2015 Results(n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 26 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.